RE:RE:RE:RE:BROKER JOSH SAYSThis guy just touched on a key point regarding q4 financials. They will be the biggest disappointment yet and the catalyst that will send this into the 5s. Everyone is expecting a run up to financials, but it won't happen, just like how everyone was expecting gains with legislation. It will hover waiting to hear...dissapointment. There will be losses from Mettrum (which was one of the dumbest moves this company has made) and losses on their biological gains, which they've been conveniently sneaking in as revenue on the bottom line. Costs per gram have gone up, not down. Average cost of gram sold has gone down, not up. Of course, these are just my predictions based on my own projections following along and paying attention, same trend happened with Aphria, and they're way more fiscally responsible than these guys. Good luck. Bloodbath on Friday.
GoBlue2016 wrote: Mangler
Mettrum had negative cash flow too.
Two negatives do not equal a positive.
GoBlue
Mangler85 wrote: SlickRick40 wrote: Josh Donaldson only buys companies with positive cash flow. WEED operational cash flow remains negative. Operations are being funded with money raised during legalization hysteria.
lol, they got metrum did they not ?